📍 Exhibit Hall
⏰ 12:15 -1:45pm and 5:35 - 7:00pm

Greg Sawyer, PhD
273: Super-resolution high-speed video microscopy reveals rapid cytotoxicity and cooperative dynamics of folate receptor alpha CAR T cells against ovarian cancer

Peter Forsyth, MD
349: A transcriptomic analysis of a first in human phase I trial of intrathecal dendritic cells in patients with leptomeningeal disease show development of adaptive immune responses

Mihaela Druta, MD 
523: Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC

David Nubaum, MD
1321: A phase I clinical trial of intravesical therapy with autologous tumor infiltrating lymphocytes (TIL) in BCG-exposed non-muscle invasive bladder cancer

Daniel Abate-Daga, PhD
369: Chimeric antigen receptor-engineered TIL (CAR-TIL) show potent tumor recognition and greater tumor infiltration than conventional CAR-T cells
12:38 - 12:46pm
Maryland Ballroom AB

Kenneth Tsai, MD, PhD
1346: Molecular and immunologic correlates of response in a phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma
3:05 - 3:15pm
Potomac Ballroom

📍 Exhibit Hall
⏰ 12:15 - 1:45pm and 5:10 - 6:35pm

Ahmad Tarhini, MD, PhD
156: A novel polygenic risk score predicts immune checkpoint inhibitor-mediated dermatitis in a North American high-risk melanoma patient population

Mihaela Druta, MD
322: Single-cell RNA sequencing of afamitresgene autoleucel indicates mechanisms of persistence and anti-tumor activity

Fatema Khambati
332: Enrichment of tumor-specific neoantigen reactive tumor infiltrating lymphocytes (TIL) in bladder cancer

Marine Potez
378: Renal Cell Carcinoma TIL expansion in controlled hypoxia enhances function and Tissue-Resident Memory phenotype

Christopher Polera
696: Turning metabolic adaptations into immunotherapeutic opportunities: RAS inhibition reshapes the tumor immunopeptidome

Kenneth Tsai, MD, PhD
878: Pathway-Synthetic Senescence as a Means to Augment Immunotherapy Response

Andrew Deonarine
1280: Lung Cancer Cells Sample Local and Systemic Sources for MHC-II Presentation

Kenneth Tsai, MD, PhD
Concurrent Session 205b
529: Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)
12:46-12:54pm
Maryland Ballroom CD

Lilit Karapetyan, MD
1340: Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma
1:45 - 2:00pm
Potomac Ballroom

Kedar Kirtane, MD
Concurrent Session 207a
Co-Chair: Cellular Therapies for Solid Tumors, Cell Therapies beyond CAR T Cells
3:30-5:10pm
Potomac Ballroom